IBRX News

Pomerantz LLP Calls Attention to Class Action Filed Against ImmunityBio, Inc. – IBRX

IBRX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that ImmunityBio, Inc. Stockholders Have Opportunity to Lead Class Action Lawsuit!

ROSEN, NATIONAL INVESTOR RIGHTS COUNSEL, Encourages ImmunityBio, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - IBRX

ImmunityBio, Inc. Securities Fraud Class Action Result of FDA Warning and 21% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC

ROSEN, A LONGSTANDING FIRM, Encourages ImmunityBio, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - IBRX

ImmunityBio, Inc. (IBRX) Facing Securities Class Action Amid FDA Warning Regarding Unsupported Cancer Treatment Claims, $2 Billion Market Capitalization Wiped Out -- Hagens Berman

DEADLINE ALERT for SMCI, IBRX, and PINS: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders

DEADLINE ALERT for ATRA, COTY, SMCI, IBRX: Law Offices of Howard G. Smith Reminds Investors of Opportunity to Lead Securities Fraud Class Actions

ImmunityBio Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against ImmunityBio, Inc. - IBRX

NASDAQ: IBRX: Kessler Topaz Meltzer & Check, LLP Announces the Filing of a Securities Fraud Class Action Lawsuit Against ImmunityBio, Inc.